NASDAQ:CBAY - CymaBay Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.77
  • Forecasted Upside: 184.28 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
$4.14
▼ -0.18 (-4.17%)
1 month | 3 months | 12 months
Get New CymaBay Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CBAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CBAY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.77
▲ +184.28% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $11.77, with a high forecast of $15.00 and a low forecast of $7.00. The average price target represents a 184.28% upside from the last price of $4.14.
Buy
The current consensus among 12 polled investment analysts is to buy stock in CymaBay Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/24/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/23/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/22/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/20/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/31/2021Cantor FitzgeraldLower Price TargetHold ➝ Overweight$20.00 ➝ $7.00Medium
i
Rating by A. Young at Cantor Fitzgerald
3/9/2021Piper SandlerReiterated RatingBuy$12.00Low
i
Rating by Yasmeen Rahimi at Piper Sandler
11/30/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$9.00 ➝ $10.00High
i
11/30/2020Smith Barney CitigroupBoost Price Target$9.00 ➝ $10.00Low
i
11/6/2020Raymond JamesBoost Price TargetStrong-Buy$11.00 ➝ $12.00High
i
11/6/2020SVB LeerinkBoost Price TargetOutperform$8.00 ➝ $10.00High
i
Rating by T. Smith at SVB Leerink LLC
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by A. Young at Cantor Fitzgerald
9/29/2020Lifesci CapitalReiterated RatingOutperformMedium
i
Rating by P. Dolezal at Lifesci Capital
9/10/2020OppenheimerReiterated RatingBuy$14.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/9/2020B. RileyBoost Price Target$9.00 ➝ $13.00High
i
Rating by Mayank Mamtani at B. Riley
8/25/2020CitigroupBoost Price TargetBuy$7.00 ➝ $9.00Medium
i
8/12/2020B. RileyReiterated RatingBuy$9.00Low
i
Rating by Mayank Mamtani at B. Riley
8/11/2020Raymond JamesBoost Price TargetStrong-Buy$10.00 ➝ $11.00High
i
8/4/2020Cantor FitzgeraldBoost Price TargetOverweight$15.00 ➝ $20.00High
i
Rating by E. Merle at Cantor Fitzgerald
8/4/2020HC WainwrightBoost Price TargetBuy$9.00 ➝ $13.00High
i
Rating by E. Arce at HC Wainwright
8/4/2020B. RileyReiterated RatingBuy$9.00High
i
Rating by Mayank Mamtani at B. Riley
8/3/2020OppenheimerInitiated CoverageBuy$12.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/3/2020Stifel NicolausBoost Price TargetHold ➝ Buy$8.00 ➝ $13.00High
i
7/30/2020Piper SandlerInitiated CoverageOverweight$12.00High
i
7/23/2020OppenheimerBoost Price TargetHold ➝ Outperform$6.00 ➝ $10.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/23/2020Raymond JamesUpgradeOutperform ➝ Strong-BuyHigh
i
6/22/2020B. RileyReiterated RatingBuy$6.00High
i
Rating by Mayank Mamtani at B. Riley
5/26/2020HC WainwrightUpgradeNeutral ➝ Buy$9.00Medium
i
Rating by E. Arce at HC Wainwright
5/15/2020CitigroupBoost Price TargetBuy$1.60 ➝ $7.00Low
i
5/12/2020B. RileyUpgradeNeutral ➝ Buy$1.50 ➝ $6.00Medium
i
Rating by Mayank Mamtani at B. Riley
5/12/2020Roth CapitalUpgradeNeutral ➝ Buy$15.00High
i
Rating by Y. Rahimi at Roth Capital
5/12/2020Cantor FitzgeraldBoost Price TargetHold ➝ Overweight$5.00 ➝ $15.00High
i
Rating by E. Merle at Cantor Fitzgerald
5/12/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$2.50 ➝ $6.00High
i
Rating by Pasha Sarraf at SVB Leerink LLC
5/12/2020Stifel NicolausUpgradeHold ➝ Buy$4.00 ➝ $8.00High
i
Rating by Derek Archila at Stifel Nicolaus
5/12/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$7.00High
i
Rating by Steven Seedhouse at Raymond James
5/12/2020Evercore ISIUpgradeIn-Line ➝ Outperform$15.00High
i
Rating by Joshua Schimmer at Evercore ISI
3/20/2020CitigroupLower Price TargetBuy$2.00 ➝ $1.60Low
i
3/18/2020B. RileyLower Price TargetNeutral$2.00 ➝ $1.50High
i
Rating by Mayank Mamtani at B. Riley
3/13/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$2.00 ➝ $5.00High
i
Rating by E. Merle at Cantor Fitzgerald
3/12/2020OppenheimerUpgradeMarket Perform ➝ Buy$4.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/30/2020HC WainwrightReiterated RatingHoldHigh
i
Rating by E. Arce at HC Wainwright
1/2/2020SVB LeerinkReiterated RatingMarket PerformMedium
i
Rating by T. Smith at SVB Leerink LLC
12/20/2019HC WainwrightReiterated RatingNeutralLow
i
Rating by E. Arce at HC Wainwright
11/27/2019B. RileyReiterated RatingHold$2.00Low
i
Rating by Mayank Mamtani at B. Riley
11/26/2019Roth CapitalDowngradeBuy ➝ Neutral$22.00 ➝ $2.00High
i
Rating by Y. Rahimi at Roth Capital
11/26/2019HC WainwrightDowngradeBuy ➝ Neutral$16.00 ➝ $2.00High
i
Rating by E. Arce at HC Wainwright
11/26/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$20.00 ➝ $2.00High
i
Rating by Eliana Merle at Cantor Fitzgerald
11/26/2019Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
i
Rating by Steven Seedhouse at Raymond James
11/25/2019OppenheimerDowngradeOutperform ➝ HoldN/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/25/2019SunTrust BanksDowngradeBuy ➝ HoldN/A
i
11/25/2019Stifel NicolausDowngradeBuy ➝ Hold$4.00N/A
i
11/24/2019Evercore ISIReiterated RatingBuy$12.00High
i
11/6/2019HC WainwrightReiterated RatingBuyMedium
i
Rating by E. Arce at HC Wainwright
9/18/2019Cantor FitzgeraldSet Price TargetBuy$20.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
8/14/2019Evercore ISIReiterated RatingBuy$15.00Low
i
6/24/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$14.00Low
i
6/17/2019B. RileySet Price TargetHold$7.00Low
i
Rating by Mayank Mamtani at B. Riley
6/13/2019CitigroupLower Price TargetBuy$21.00 ➝ $12.00High
i
Rating by Joel Beatty at Citigroup Inc.
6/12/2019HC WainwrightReiterated RatingBuy$24.00 ➝ $12.00Low
i
6/11/2019B. RileySet Price TargetHold$11.00High
i
Rating by Mayank Mamtani at B. Riley
6/11/2019OppenheimerSet Price TargetBuy$12.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/11/2019Piper Jaffray CompaniesLower Price TargetOverweight ➝ Buy$30.00 ➝ $8.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
5/14/2019CitigroupInitiated CoverageBuy ➝ Buy$21.00 ➝ $21.00High
i
4/23/2019Raymond JamesSet Price TargetBuy$18.00Low
i
Rating by Steven Seedhouse at Raymond James
4/14/2019OppenheimerSet Price TargetBuy$18.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/14/2019Cantor FitzgeraldSet Price TargetBuy$20.00Medium
i
Rating by Eliana Merle at Cantor Fitzgerald
3/1/2019Piper Jaffray CompaniesSet Price TargetBuy$30.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
2/28/2019Cantor FitzgeraldSet Price TargetBuy$20.00High
i
Rating by Eliana Merle at Cantor Fitzgerald
2/22/2019SVB LeerinkInitiated CoverageOutperform$22.00High
i
2/21/2019SVB LeerinkReiterated RatingOutperformMedium
i
Rating by J. Schwartz at SVB Leerink LLC
2/20/2019Piper Jaffray CompaniesSet Price TargetBuy$30.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
2/19/2019Roth CapitalReiterated RatingBuyLow
i
Rating by Y. Rahimi at Roth Capital
2/15/2019OppenheimerSet Price TargetBuy$18.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/5/2019B. RileyInitiated CoverageHold$9.00 ➝ $9.00Medium
i
Rating by Mayank Mamtani at B. Riley
2/1/2019Cantor FitzgeraldReiterated RatingBuy$20.00High
i
Rating by E. Merle at Cantor Fitzgerald
12/9/2018OppenheimerSet Price TargetBuy$18.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by E. Merle at Cantor Fitzgerald
11/19/2018HC WainwrightReiterated RatingBuyHigh
i
11/13/2018OppenheimerSet Price TargetBuy$18.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/7/2018OppenheimerSet Price TargetBuy$18.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/7/2018Cantor FitzgeraldSet Price TargetBuy$17.00High
i
Rating by William Tanner at Cantor Fitzgerald
10/5/2018OppenheimerSet Price TargetBuy$20.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/10/2018Piper Jaffray CompaniesBoost Price TargetOverweight$30.00Low
i
8/9/2018OppenheimerSet Price TargetBuy$20.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/9/2018Cantor FitzgeraldReiterated RatingBuy$16.00High
i
6/28/2018Raymond JamesInitiated CoverageOutperform$20.00Medium
i
6/6/2018HC WainwrightReiterated RatingBuy$21.00 ➝ $23.00Medium
i
5/9/2018OppenheimerSet Price TargetBuy$20.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/17/2018OppenheimerSet Price TargetBuy$20.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/13/2018HC WainwrightBoost Price TargetBuy$21.00Low
i
4/11/2018OppenheimerSet Price TargetBuy$18.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/11/2018SVB LeerinkBoost Price TargetOutperform$16.00 ➝ $20.00High
i
3/28/2018HC WainwrightInitiated CoverageBuy$18.00Medium
i
3/21/2018OppenheimerReiterated RatingBuyMedium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/16/2018SunTrust BanksReiterated RatingBuy$19.00High
i
3/16/2018Piper Jaffray CompaniesReiterated RatingBuy$16.00High
i
3/16/2018Cantor FitzgeraldReiterated RatingBuy$16.00Low
i
Rating by W. Tanner at Cantor Fitzgerald
3/12/2018OppenheimerSet Price TargetBuy$18.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/13/2018Evercore ISIInitiated CoverageOutperform ➝ OutperformHigh
i
1/25/2018Roth CapitalReiterated RatingBuy ➝ Buy$27.00High
i
Rating by Y. Rahimi at Roth Capital
1/24/2018HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $18.00High
i
1/10/2018OppenheimerSet Price TargetBuy$15.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/28/2017SVB LeerinkReiterated RatingBuy$16.00High
i
Rating by J. Schwartz at SVB Leerink LLC
11/28/2017HC WainwrightReiterated RatingBuy$12.00Low
i
11/8/2017Cantor FitzgeraldReiterated RatingBuy$16.00N/A
i
Rating by W. Tanner at Cantor Fitzgerald
10/30/2017OppenheimerSet Price TargetBuy$15.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$12.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/26/2017Cantor FitzgeraldReiterated RatingBuy$16.00High
i
Rating by W. Tanner at Cantor Fitzgerald
9/19/2017Cantor FitzgeraldInitiated CoverageOverweight$16.00High
i
Rating by W. Tanner at Cantor Fitzgerald
8/23/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$12.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
8/18/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$15.00High
i
8/11/2017Ifs SecuritiesDowngradeStrong-Buy ➝ OutperformHigh
i
Rating by D. Bouchey at Ifs Securities
7/25/2017Piper Jaffray CompaniesReiterated RatingPositive ➝ Overweight$12.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
7/20/2017CIBCReiterated RatingOutperform ➝ Outperform$8.00 ➝ $15.00Medium
i
7/20/2017OppenheimerBoost Price TargetOutperform$8.00 ➝ $15.00Medium
i
7/20/2017CitigroupReiterated RatingOutperform$8.00 ➝ $15.00Medium
i
7/17/2017Ifs SecuritiesReiterated RatingStrong-BuyLow
i
Rating by D. Bouchey at Ifs Securities
7/17/2017Piper Jaffray CompaniesSet Price TargetBuy$7.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
7/17/2017HC WainwrightBoost Price TargetBuy$7.00 ➝ $12.00High
i
Rating by E. Arce at HC Wainwright
6/23/2017OppenheimerInitiated CoverageOutperform$8.00High
i
3/27/2017HC WainwrightReiterated RatingBuy$6.00 ➝ $7.00High
i
Rating by E. Arce at HC Wainwright
3/24/2017Piper Jaffray CompaniesBoost Price TargetOverweight$5.00 ➝ $6.50High
i
1/30/2017HC WainwrightUpgradeNeutral ➝ Buy$2.50 ➝ $6.00N/A
i
Rating by E. Arce at HC Wainwright
1/4/2017HC WainwrightBoost Price TargetNeutral$1.50 ➝ $2.50N/A
i
7/1/2016Roth CapitalInitiated CoverageBuyN/A
i
Rating by S. Yaniv at Roth Capital
6/1/2016HC WainwrightDowngradeBuy ➝ Neutral$6.00 ➝ $2.25N/A
i
Rating by Ed Arce at HC Wainwright
5/12/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Ed Arce at HC Wainwright
(Data available from 4/19/2016 forward)
CymaBay Therapeutics logo
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Read More

Today's Range

Now: $4.14
$4.14
$4.41

50 Day Range

MA: $4.68
$4.19
$5.18

52 Week Range

Now: $4.14
$1.50
$9.06

Volume

36,512 shs

Average Volume

1,132,079 shs

Market Capitalization

$285.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of CymaBay Therapeutics?

The following Wall Street sell-side analysts have issued research reports on CymaBay Therapeutics in the last twelve months: B. Riley, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Evercore ISI, HC Wainwright, Lifesci Capital, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Roth Capital, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for CBAY.

What is the current price target for CymaBay Therapeutics?

13 Wall Street analysts have set twelve-month price targets for CymaBay Therapeutics in the last year. Their average twelve-month price target is $11.77, suggesting a possible upside of 184.3%. Roth Capital has the highest price target set, predicting CBAY will reach $15.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $7.00 for CymaBay Therapeutics in the next year.
View the latest price targets for CBAY.

What is the current consensus analyst rating for CymaBay Therapeutics?

CymaBay Therapeutics currently has 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CBAY will outperform the market and that investors should add to their positions of CymaBay Therapeutics.
View the latest ratings for CBAY.

What other companies compete with CymaBay Therapeutics?

How do I contact CymaBay Therapeutics' investor relations team?

CymaBay Therapeutics' physical mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company's listed phone number is 510-293-8800 and its investor relations email address is [email protected] The official website for CymaBay Therapeutics is www.cymabay.com.